日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)

Talimogene laherparepvec 和 atezolizumab 在新辅助化疗后 HER2 阴性乳腺癌中的应用:一项机会窗口 II 期试验 (SOLTI-1503 PROMETEO)

Pascual, Tomás; Vidal, Maria; Cejalvo, Juan M; Vega, Estela; Sanfeliu, Esther; Villacampa, Guillermo; Ganau, Sergi; Parreño, Ana María Julve; Zamora, Esther; Miranda, Ignacio; Delgado, Ana; Bermejo, Begoña; Seguí, Elia; Brasó-Maristanty, Fara; de la Cruz-Merino, Luis; Juan, Manel; Galván, Patricia; Gonzàlez-Farré, Xavier; Chillara, Samyukta; Villagrasa, Patricia; Pfefferle, Adam D; O'Connell, Constandina E; Ferrero-Cafiero, Juan M; Oliveira, Mafalda; Perou, Charles M; Prat, Aleix

Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial

新辅助帕博西尼联合内分泌治疗与化疗治疗ER+/HER2-乳腺癌:一项随机II期试验

Matikas, Alexios; Tzoras, Evangelos; Sarafidis, Michail; Sifakis, Emmanouil G; Bjöhle, Judith; Barnekow, Elin; Margolin, Sara; Isaksson-Friman, Erika; Kessler, Luisa Edman; Zouzos, Athanasios; Johansson, Hemming; Hellström, Mats; Agartz, Susanne; Grybäck, Per; Salgkamis, Dimitrios; Zerdes, Ioannis; Wang, Kang; Hartman, Johan; Acs, Balazs; Sun, Wenwen; Boyaci, Ceren; Villacampa, Guillermo; Pascual, Tomas; Gavila, Joaquin; Prat, Aleix; Perou, Charles; Brandberg, Yvonne; Bergh, Jonas; Hatschek, Thomas; Foukakis, Theodoros

Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

HER2DX基因组检测与HER2阳性乳腺癌生物学和病理特征的关联

Sanfeliu, Esther; Martínez-Romero, Anabel; Marín-Aguilera, Mercedes; Cobo, Sandra; González-Farré, Blanca; Hernandez-Illan, Eva; Jares, Pedro; Puig-Butillé, Joan Antón; Muñoz, Montserrat; Gómez-Bravo, Raquel; Tapia, Marta; Tebar, Cristina; Saura, Cristina; Escrivà-de-Romaní, Santiago; Soberino, Jesús; Cortés, Javier; Morales, Serafin; Amillano, Kepa; Paré, Laia; Villagrasa, Patricia; Buckingham, Wesley; Pardo, Francisco; Parker, Joel S; Brasó-Maristany, Fara; Ciruelos, Eva; Sánchez-Bayona, Rodrigo; Martinez-Sáez, Olga; Cejalvo, Juan Miguel; Prat, Aleix

Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes

帕博利珠单抗联合紫杉醇治疗 HR+/HER2- 乳腺癌患者,包括 HER2 富集型或基底样亚型

Conte, Benedetta; Brasó-Maristany, Fara; Pascual, Tomás; Hernando, Cristina; Vázquez, Silvia; Blanch, Salvador; Oliveira, Mafalda; Virizuela, Juan Antonio; Muñoz, Montserrat; Seguí, Elia; Rodriguez-Hernandez, Adela; Vidal Losada, Maria Jesus; Galván, Patricia; Castillo, Oleguer; Blasco, Paula; Alva, Manuel; Chic, Nuria; Sanfeliu, Esther; Cano-Crespo, Sara; Salvador, Fernando; Villacampa, Guillermo; Villanueva, Lorea; Ferrero-Cafiero, Juan Manuel; Vivancos, Ana; Prat, Aleix; Ciruelos, Eva

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

定量 HER2 组织和血浆分析可预测曲妥珠单抗 deruxtecan 对乳腺癌的活性。

Tarantino Paolo, Kim Se-Eun, Hughes Melissa E, Kusmick Ross J, Smith Kalie, Brasó-Maristany Fara, Nyein Chan Nay Nwe, Paré Brunet Laia, Alder Laura, Garcia-Cortes Diana, Gomez Tejeda Zanudo Jorge, Pereslete Alyssa M, Noteware Laura, Moore Heather, Van Swearingen Amanda E D, Li Tianyu, Gupta Hersh, D'Amico Olivia, Martini Alba, Morganti Stefania, Spindel Jennifer, Cook Charmaine, McLaughlin Christine, Dvir Kathrin, Garrido-Castro Ana C, Sammons Sarah, Files Janet, Sendrick Kerry, Buck Simone, Dillon Deborah, Jeselsohn Rinath, Li Yvonne Y, Cherniack Andrew D, LoRusso Patricia, Lustberg Maryam, Vega-León Rosario, Pardo Francisco, Davis Justin, Mueller Claudius, Corgiat Brian, Curigliano Giuseppe, Anders Carey K, Petricoin Emanuel F, Rimm David L, Prat Aleix, Tayob Nabihah, Lin Nancy U, Tolaney Sara M

Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology

激素受体阳性/HER2阴性乳腺癌试验中的动态生物标志物:精准肿瘤学的新希望

Di Grazia, Giuseppe; Sánchez-Bayona, Rodrigo; Casals-Pascual, Climent; Pascual, Tomás; Generali, Daniele; Gennari, Alessandra; Vigneri, Paolo; Harbeck, Nadia; Cortés, Javier; Prat, Aleix; Schettini, Francesco

Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane

验证 HER2DX 基因组检测在接受曲妥珠单抗、帕妥珠单抗和紫杉烷一线治疗的 HER2 阳性晚期乳腺癌患者中的应用价值

Kubeczko, Marcin; Cobo, Sandra; Sanchez-Bayona, Rodrigo; Pyciński, Bartłomiej; Soberino, Jesús; Chmielik, Ewa; Sanfeliu, Esther; Rey, Maria; Pardo, Francisco; Aguirre, Angela; Castillo, Oleguer; Lesniak, Aleksandra; Oczko-Wojciechowska, Malgorzata; Carcelero, Esther; Adamo, Barbara; Vidal, Maria; Bergamino, Milana; Maues, Julia; Villacampa, Guillermo; Paré, Laia; Villagrasa, Patricia; Ciruelos, Eva; Prat, Aleix; Jarzab, Michal; Brasó-Maristany, Fara

Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study

SOLTI-1801 CDK-PREDICT 研究:在 HR+/HER2- 转移性乳腺癌患者中,一线 CDK4/6 抑制剂治疗进展后,根据 PAM50 内在亚型评估二线和三线治疗的真实世界无进展生存期

Tolosa, Pablo; García-Fructuoso, Isabel; Pascual, Tomás; Martínez-Sáez, Olga; Cejalvo, Juan Miguel; Servitja, Sonia; Fernández Abad, María; Benitez Fuentes, Javier David; Brasó-Maristany, Fara; Sanfeliu, Ester; Lema, Laura; Ruano, Yolanda; Parrilla, Lucía; Roncero, Ana María; Cobos, María Ángeles; Díaz, Irene; Centelles López, Karla Alicia; Sánchez-Bayona, Rodrigo; Alva, Manuel; Madariaga, Ainhoa; Villacampa, Guillermo; Salvador, Fernando; Sánchez-Belmonte, Agustín; Malumbres, Marcos; Prat, Aleix; Ciruelos, Eva

Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospects

加泰罗尼亚公共卫生系统精准肿瘤学项目的实施:成果、经验教训和未来展望

Mur, Pilar; Pozuelo, Anna; Tabernero, Josep; Albanell, Joan; Bellosillo, Beatriz; Bosch, Francesc; Briones, Javier; Brunet, Joan; Colomer, Dolors; Domènech, Montserrat; Fontanet, Joan Manel; Matias-Guiu, Xavier; Salazar, Ramon; Vivanco-Hidalgo, Rosa Maria; Mollà, Meritxell; Moreno, Lucas; Prat, Aleix; Ribera, Josep Maria; Clèries, Ramón; Guarga, Alex; Espinàs, Josep A; Borras, Josep Maria

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

曲妥珠单抗德鲁替康治疗HER2低表达转移性乳腺癌:随机3期DESTINY-Breast04试验的长期生存分析

Modi, Shanu; Jacot, William; Iwata, Hiroji; Park, Yeon Hee; Vidal Losada, Maria; Li, Wei; Tsurutani, Junji; Ueno, Naoto T; Zaman, Khalil; Prat, Aleix; Papazisis, Konstantinos; Rugo, Hope S; Yamashita, Toshinari; Harbeck, Nadia; Im, Seock-Ah; De Laurentiis, Michelino; Pierga, Jean-Yves; Wang, Xiaojia; Gombos, Andrea; Tokunaga, Eriko; Orbegoso Aguilar, Cecilia; Yung, Lotus; Xiao, Feng; Cheng, Yingkai; Cameron, David